English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 915914      Online Users : 1298
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version

    Category

    Loading community tree, please wait....

    Year

    Loading year class tree, please wait....

    Items for Author "Valle, JW" 

    Return to Browse by Author

    Showing 15 items.

    Collection Date Title Relation Bitstream
    [陳立宗] 會議論文/會議摘要 2022-11 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [陳立宗] 會議論文/會議摘要 2022-09 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [陳立宗] 會議論文/會議摘要 2022-06 Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements -
    [陳立宗] 會議論文/會議摘要 2022-02-01 A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 -
    [陳立宗] 會議論文/會議摘要 2021-09 Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements -
    [陳立宗] 會議論文/會議摘要 2021-07 Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements -
    [陳立宗] 會議論文/會議摘要 2020-02 Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study -
    [陳立宗] 會議論文/會議摘要 2019-10 A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 -
    [陳立宗] 會議論文/會議摘要 2019-02 A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements -
    [陳立宗] 期刊論文 2024-08 Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study -
    [陳立宗] 期刊論文 2024-06-17 Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer -
    [陳立宗] 期刊論文 2023-11 Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer -
    [陳立宗] 期刊論文 2023-07 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462 -
    [陳立宗] 期刊論文 2023-01-19 Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma -
    [陳立宗] 期刊論文 2021-10 Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study -

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback